

Special Issue

Pharmacotherapy of Prostate Cancer

Message from the Guest Editor

Prostate cancer has always represented a major challenge worldwide, with key issues including resistance to androgen receptor pathway inhibitors (ARPIs), neuroendocrine progression, and limited durable responses to immunotherapy. This Special Issue will highlight novel therapeutic strategies reshaping this field. We invite you to share your latest research results in this field, including, but not limited to, the following areas:

- Original research on preclinical/clinical drug development;
- Phase I-III trial results;
- Reviews on emerging targets (e.g., ferroptosis inducers, antibody–drug conjugates);
- Prostate cancer biomarkers.

We hope that this Special Issue will improve our understanding of this malignant disease and encourage discussion among frontline physicians, to improve treatment outcomes for prostate cancer patients.

Guest Editor

Prof. Dr. Benyi Li

Department of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA

Deadline for manuscript submissions

15 November 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/240788

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)